HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Tripathy Offers Perspective on HER2-Positive Breast Cancer

August 13th 2014

The ever-evolving treatment landscape for patients with HER2-positive breast cancer leaves several questions unanswered regarding therapeutic sequences and whether an optimal standard of care exists.

Utilizing Bisphosphonates in Breast Cancer

August 7th 2014

TEXT/SOFT Findings in HR-Positive Breast Cancer

August 7th 2014

Adjuvant Everolimus and CDK4/6 Trials in Breast Cancer

August 7th 2014

Managing the Toxicity of Everolimus in Breast Cancer

August 7th 2014

Second-Line Everolimus in Metastatic Breast Cancer

August 7th 2014

Frontline Treatment of ER-Positive Breast Cancer

August 7th 2014

T-DM1 Plus Pertuzumab in the MARIANNE Trial

August 7th 2014

Fitting T-DM1 Into Established Upfront Treatment Paradigms

August 7th 2014

Utilizing pCR in Breast Cancer Trials

August 7th 2014

Upfront T-DM1 in HER2-Positive Breast Cancer

August 7th 2014

HER2 Testing Challenges in Metastatic Breast Cancer

August 7th 2014

First-Line Treatment of HER2-Positive MBC

August 7th 2014

Exceptional Responders in Breast Cancer

August 7th 2014

Nab-Paclitaxel in Metastatic Breast Cancer

August 7th 2014

Introduction: Chemotherapies for Advanced Breast Cancer

August 7th 2014

Evolving Therapeutic Landscape in Breast Cancer

August 5th 2014

Case Studies: Treating Metastatic Breast Cancer

August 5th 2014

Clinical Setting for Eribulin in Metastatic Breast Cancer

August 5th 2014

Treatment Strategies in ER-Positive Breast Cancer

August 5th 2014